Asciminib (STAMP) for CML-CP 3L+ post-multi-TKI failure
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-ASCIMINIB |
|---|
| ID | REG-ASCIMINIB-CML |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ASCEMBL-REA-2021 SRC-ELN-CML-2020 SRC-NCCN-MPN-2025 |
Notes
STAMP allosteric inhibitor — mechanism distinct from all ATP-site TKIs, avoids most cross-resistance. Standard 3L+ for CML-CP post ≥2 prior TKIs per ASCEMBL. T315I requires higher dose (200 mg BID). Cardiovascular safety substantially better than ponatinib but not zero. STUB — pending Co-Lead sign-off.
Used By
Indication
IND-CML-3L-ASCIMINIB- IND-CML-3L-ASCIMINIB